-
New Hope for Lung Cancer Patients: GSK Shares Positive Data on Jideytro (zidesamtinib)
NYSE: $GSK A Major Milestone in ROS1-Positive Lung Cancer GSK has recently announced encouraging registrational data from its clinical trial program for Jideytro (zidesamtinib), a targeted therapy designed for patients living with ROS1-positive non-small cell lung cancer (NSCLC). These results represent a significant step forward in the company’s goal to bring this treatment to patients…
-
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for Ibtrozi (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
NYSE: $NUVB NEW YORK, Sept. 16, 2026 /PRNewswire/ — Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved… Source: Read More